NATREON IS GRANTED A U.S. PATENT ON ITS CROMINEX® PRODUCT!

FOR IMMEDIATE RELEASE

Natreon Inc.
2-D Janine Place
New Brunswick, NJ 08901
732-296-1080

NATREON IS GRANTED A U.S. PATENT ON ITS CROMINEX® PRODUCT!

New Brunswick, NJ, March 20, 2019 – Natreon has been granted a U.S. Patent (10,183,047, January 22, 2019) on its Crominex®3+, a composition of trivalent chromium chloride combined with extracts of amla and shilajit, that has a synergistic effect on improving lipid profile and endothelial function. This newly granted patent, along with 7 clinical studies on Crominex®3+, establish this ingredient as the ideal product for supporting heart health. This expands Natreon’s strong patent portfolio to 28 domestic and international active patents.

“We are glad that USPTO has granted a well-deserved patent for cardiovascular health benefits of Crominex®3+, the most efficacious of several chromium supplements from the market. Crominex®3+ has amazing synergistic activity that showed significant improvement in endothelial function, lipid profile, hsCRP, as well as HbA1c, which are all important factors for cardiovascular health. Synergistic activity of Crominex®3+ is achieved by using totally natural materials,” said Dr. Sanni Raju, CEO of Natreon.

Two additional clinical studies (to be published soon), show combining only 10-20 mg of Crominex®3+ (200 mcg to 400 mcg of trivalent chromium) with 2 g of fish oil (600 mg of EPA + 400 mg of DHA) enhances the health benefits of fish oil significantly.

“It is interesting to note that 10-20 mg of Crominex®3+ neither increases the size of the fish oil dosage form nor impacts the cost significantly, while enhancing fish oil’s numerous cardiovascular health benefits,” says Dr. Sanni Raju, CEO of Natreon. Continue Reading

 

FULL PRESS RELEASE

Recent Posts